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Abstract
Background: Methicillin-resistant S. pseudintermedius strains (MRSP) are reported with increasing frequency in
bacterial cultures from dogs. The objectives of this study were to determine whether MRSP could be found in
dogs several months after a clinically apparent infection and whether the length of carriage varied depending on
systemic antimicrobial treatment, diagnosis at time of the first positive MRSP culture and the presence of skin
disease or wounds. Thirty-one dogs previously diagnosed with a clinical infection were sampled repeatedly for a
minimum of eight months or, with the exception of two dogs, until two consecutive negative results were
obtained. Five specified locations were sampled, and the results were evaluated to determine future
recommendations concerning sample strategies when screening for MRSP carriage. Information was collected from
medical records and questionnaires to evaluate factors that may influence length of carriage.
Results: The overall median length of MRSP carriage was 11 months (48 weeks). The presence of wounds and
signs of dermatitis did not influence length of carriage. Systemic treatment for three weeks or longer with
antimicrobial agents to which the bacterium was resistant was associated with prolonged carriage compared to
dogs treated for a shorter period of time. Three of five dogs treated with an antimicrobial to which their MRSP-
isolates were susceptible (tetracycline) were found to still be MRSP-positive when sampled after the end of
treatment. Wound samples had the highest positive MRSP yield (81%) for the positive sample sites, compared to
less than 70% for each of the other four sample sites. Cultures from the nostrils were less likely to detect MRSP
carriage relative to the pharynx, perineum, wounds and the corner of the mouth.
Conclusions: Dogs can carry MRSP for more than a year after a clinically apparent infection. Systemic antimicrobial
treatment of infections with antimicrobial agents to which the MRSP-bacteria are resistant should be avoided when
possible in dogs with possible or confirmed MRSP carriage or infection, since it may prolong time of MRSP carriage.
Simultaneous sampling of pharynx, perineum, and the corner of the mouth as well as wounds when present is
recommended when screening for MRSP. Cultures from nostrils were shown to be less likely to detect MRSP carriage.
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Background
Staphylococcus pseudintermedius is a part of the normal
microbiota of dogs and an important opportunistic
pathogen. It is most commonly associated with derma-
tologic infections, such as pyoderma, otitis externa and
wound infections, but it is also capable of causing infec-
tions in other body tissues [1-4].
Since 2006 there has been a significant emergence of
methicillin-resistant S. pseudintermedius (MRSP), mainly
due to clonal spread [5-9]. Methicillin resistance is
mediated by the mecA gene, which encodes the penicil-
lin-binding protein (PBP) that has a low affinity for all
ß-lactam antimicrobials [10].
Data on resistance in S. pseudintermedius in isolates
from Swedish dogs referred to the National Veterinary
Institute from veterinary clinics and hospitals has been
reported since 1992 [11]. In 2006, the first 13 isolates of
MRSP in Swedish dogs were reported. In 2007 and
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[11]. This has necessitated evidence-based recommenda-
tions on infection control measures to prevent further
spread in the dog population. One central issue is
whether individual dogs, once found to be infected with
MRSP, can become long-term carriers.
The objectives of this study were to determine
whether MRSP can be found in dogs several months
after a clinically apparent infection and whether length
of carriage varies depending on systemic antimicrobial
treatment, diagnosis at the time of the first positive
M R S Pc u l t u r ea n dt h ep r e s e n c eo fs k i nd i s e a s eo r
wounds. Culture results from five sample sites were
compared.
Methods
Dogs
The 31 dogs enrolled in the study had MRSP-positive cul-
tures of clinical specimens (inclusion sample) referred
from a total of eight veterinary clinics and hospitals to the
SVA (National Veterinary Institute, Sweden) for diagnostic
purposes between October 2007 and February 2009.
A copy of each dog’s medical record was collected. In
addition, a brief questionnaire was completed by the
owner aided by the veterinarian at each sampling. The
owners were asked if the dog had received any kind of
treatment by other veterinarians before and during the
study and if any signs of illness or dermatological
changes had been noted since the last sample occasion.
Data on breed, gender, age, presenting complaint (diag-
nosis), medical treatment and antimicrobial treatment
from a year prior to the inclusion sample and during
the entire study (sampling period) were compiled.
Sample strategies
The dogs were sampled using bacterial swabs placed in
Amies medium
® (Copan Italia S.p.A Brescia Italy). Samples
were collected from four specified locations on all dogs;
nostrils, pharynx, perineum and the corner of the mouth.
Wounds were sampled when present. A separate swab was
used for each location. Dogs in the study were to be
sampled with intervals of 6-15 weeks until two negative
results were obtained or for a minimum of eight months.
Bacterial isolation, phenotypic identification and
antimicrobial susceptibility testing
The samples were transported overnight and processed
on the day of arrival at the laboratory. The swabs were
placed in 10 mL tryptone soy enrichment broth (TSB)
with 4% saline, 1% mannitol, 16 mg/L phenol, 50 mg/L
aztreonam (MP Biomedicals) [12,13] modified by using
1 mg/L of cefoxitin (Sigma-Aldrich). After 48 hour incu-
bation at 37°C, 10 μL of broth was plated onto two
media: bovine blood-agar (National Veterinary Institute,
Uppsala, Sweden) and mannitol salt agar with lithium
chloride (Oxoid Ltd, Merck KGaA).
The plates were incubated aerobically at 37°C for 48
hours. Colonies were identified as suspected members of
the S. intermedius species group (SIG) based on colony
morphology, production of haemolytic toxins, coagula-
tion of plasma, DNAse production and aerobic acid pro-
duction from bromcresol-purple agar with 1% maltos
and trehalose broth (SVA, Uppsala, Sweden).
All suspected SIG isolates were tested for susceptibil-
ity to oxacillin. The resistance breakpoint of ≥ 0.5 mg/L
for oxacillin was used as an indicator for methicillin
resistance. This breakpoint was recommended by Bemis
and co-workers [14], and it has recently been approved
by the CLSI subcommittee on Veterinary Antimicrobial
Susceptibility Testing [15]. Isolates found to be resistant
were examined further by polymerase chain reaction
(PCR), as described below. MRSP isolates from the
inclusion sample and from the last sample occasion
were in addition tested for susceptibility to the following
antimicrobial agents: penicillin, cephalothin, erythromy-
cin, chloramphenicol, clindamycin, tetracycline, fusidic
acid, gentamicin, kanamycin, ciprofloxacin and tri-
methoprim. Minimum inhibitory concentrations (MICs)
of the antimicrobial agents were determined by broth
microdilution, according to the recommendations of the
Clinical and Laboratory Standards Institute (CLSI) [16]
using VetMIC microdilution panels (National Veterinary
Institute, Uppsala, Sweden). S. aureus ATCC 29213
served as quality control strain. The MIC breakpoints
for classification of isolates as resistant were those
recommended for Staphylococcus species in CLSI docu-
ments M100-S19 and M31-A3 [17,18]. For fusidic acid,
the clinical breakpoint for S. aureus defined by the Eur-
opean Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) [19] was used.
Molecular identification and PCR detection of mecA
DNA extraction was performed according to Capurro
et al. [20]. Fragments corresponding to the 16S rRNA
gene and the SIG specific thermonuclease gene were
analysed by multiplex-PCR, as described previously by
Baron et al. [21]. Detection of the mecA gene was per-
formed in a single PCR [22]. As all isolates were from
dogs, isolates positive for both the thermonuclease gene
and the mecA gene were considered to be MRSP as pre-
viously described [5,7,23-25].
Typing of strains
F o r2 6o ft h e2 7d o g sw h i c hw e r ef o u n dt ob eM R S P -
positive on one or more sample occasions following the
inclusion sample, an isolate from the last positive sam-
ple occasion could be compared to either the inclusion
sample (n = 21) or the first sample collected after
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(PFGE). The dog whose inclusion isolate was lost to fol-
low up was found to be negative on the following sam-
ple occasion, within 26 weeks (6 months) from the
inclusion sample. SmaI macrorestriction patterns were
obtained using the standardised HARMONY protocol
[26], but with the pulse switch times as described by
Perreten et al. [7]. For comparison of SmaIp a t t e r n s ,
cluster analysis was performed by comparing gel images
using the BioNumerics software (version 4.5; Applied
Maths, Sint-Martens-Latem, Belgium).
Statistical analyses
The outcome of interest, MRSP-negativity, was in this
study defined as the cultures from all sample sites being
MRSP-negative on two consecutive sample occasions.
Length of MRSP-carriage was defined as time from the
inclusion sample until the first of two consecutive nega-
tive sample occasions, with the exception of two dogs
that were found to be negative on only one sample
occasion, after which they left the study. These two
dogs were therefore regarded as MRSP-negative on that
last sample occasion.
The Kaplan-Meier (product limit) method was used to
create probability curves for length of MRSP carriage as
w e l la st h em e d i a nt i m e( i . e . ,w h e n5 0 %o ft h ed o g s
were found to be MRSP-negative). This was done cru-
dely, as well as by gender, age, diagnosis at time of
inclusion sample, presence of dermatitis or wounds dur-
ing the study, and relative to the time during which the
dogs had received systemic treatment with antimicrobial
agents to which the cultured MRSP were resistant. All
such antimicrobial treatment received within three
months prior to and during the study period was
included in the analysis. For comparison, the median
time of carriage was in addition calculated with the last
positive sample occasion for each dog as the end of
MRSP carriage.
In the analysis, gender was categorised as male or
female with no distinction between intact and spayed or
neutered dogs. Six years was the mean and median age
of the population and for the age variable, dogs ≤ 6
years (n = 17) was contrasted to older dogs (n = 14).
The variable “length of antibiotic treatment” was cate-
gorised in two groups. Length of treatment ≥ 21 days
with antimicrobials to which the cultured MRSP bac-
teria were resistant was contrasted to shorter treatment
periods. Diagnosis at time of inclusion sample was cate-
gorised into three diagnostic categories: dermatitis (n =
11), surgical procedures (n = 13) or infection/trauma (n
= 7), according to the clinical diagnosis made by the
veterinarians sampling the dogs. At the stratification,
the log-rank test was used to test whether probability
curves differed and p < 0.05 was considered significant.
The median number of positive sample sites (wounds
excluded) found in each dog per positive sample occa-
sion relative to presence of wounds and dermatitis
respectively was compared. All statistical analyses above
were performed using SAS statistical software (SAS ver-
sion 9.1, SAS Institute Inc., Cary NC). The nonpara-
metric two-sample Mann-Whitney Test (Minitab) was
used to compare the median number of positive sample
sites found in each dog per positive sample occasion
relative to presence of wounds and dermatitis
respectively.
Ethics
The study was approved by the Swedish Board of Agri-
culture and the Ethical Committee on Animal Experi-
ments in Uppsala. Written consent from each dog
owner was collected by the veterinarian on each sample
occasion using a specific consent form approved by the
Ethical committee.
Results
Twenty-four breeds were represented, only three of
which were observed in more than one individual dog.
Four dogs were of mixed breed. Mean and median age
at the time of the inclusion sample was six years (range
1-12 years). Sixteen of the 31 sampled dogs were intact
females, nine were intact males, three were spayed
females, and three were neutered males.
Thirteen dogs were diagnosed as having post-operative
infections at the time of the inclusion sample. Eleven
dogs were diagnosed with dermatitis at the time of the
inclusion sample. The remaining seven dogs were trea-
ted for traumatic injuries or secondary infection.
Six of the eleven dogs with dermatitis at the time of
the inclusion sample had recurrence of skin disease later
during the study. Signs of dermatitis were present on
ten sample occasions, three of which yielded negative
results from all sample sites. Only one of the 31 dogs
(dog No. 20, Additional file 1: Table S1) showed other
clinical signs of infection during the sampling period.
That dog had an oronasal fistula and a yellow, thick
nasal discharge was noted by the owner daily during the
entire study period.
All dogs received systemic treatment with antimicro-
bial agents to which the cultured MRSP were resistant
prior to the first sample occasion in the study. Median
length of treatment was 24 days. No dogs received
further treatment with such antimicrobials during the
study, and in approximately two thirds (n = 20) of the
dogs, the treatment was ended prior to, or at the time
of, the inclusion sample. Five dogs received systemic
treatment with tetracycline, an antimicrobial agent to
which the cultured MRSP isolates were susceptible. The
treatment was ended prior to the first sample occasion
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tional file 1: Table S1) was the only dog in the study
receiving any antimicrobial treatment after the first sam-
ple occasion of the study. The median length of treat-
ment with tetracycline was 30 days (range 20-60 days).
The SmaIr e s t r i c t i o n sp r o f i l e ss h o w e d8 5 %o rm o r e
similarity between the two isolates compared by PFGE
from each dog (Figure 1). With the exception of isolates
found in dog number 17 and 20, the MRSP-isolates
tested for antimicrobial susceptibility showed similar
antibiograms, being suscept i b l eo n l yt of u s i d i ca c i da n d
tetracycline. The isolates with diverging results were
found to be resistant to tetracycline.
Twenty-nine out of the 31 dogs were sampled accord-
ing to plan regarding length of follow-up. Two dogs
were only available for sampling for 5.5 and 6 months,
respectively. All samples were collected according to the
planned minimum interval and 60% within the planned
3.5 month maximum interval. The median study period
w a s1 0m o n t h s( r a n g e4 . 5 - 1 9 ) ,a n dt h em e d i a nn u m b e r
of sample occasions per dog was 3 (range 2-6). The
median time between sample occasions was 2.5 months
(Additional file 1: Table S1, Figure 2).
Five dogs remained MRSP-positive for more than 14
months (61 weeks). Nine dogs were sampled for 5-12
months (22-52 weeks) and remained positive. One of
these dogs had a negative result on one sample occasion
followed by positive results. Fifteen dogs were found to
be negative within 12 months (52 weeks) and they
remained negative 3.5 to 7.5 months later (15-33
weeks). Two dogs left the study at five and ten months,
respectively, with negative results from all sample sites
at the final sample occasion (Additional file 1: Table S1).
The overall median length of MRSP carriage was 11
months (48 weeks) (Figure 3). When the last positive
sample occasion was used as the end of MRSP carriage
the median time of carriage was 45 weeks. No signifi-
cant differences in length of MRSP carriage appeared
either between the three diagnostic categories (p = 0.31)
or in the dogs with dermatitis on the following sample
occasions in the study compared to dogs with no visible
signs of skin disorder (p = 0.78). Possible influence of
breed could not be evaluated from the material due to
the wide variety of breeds being represented in the rela-
tively small number of dogs. There was no significant
difference in the length of carriage between the two age
groups: ≤ 6 years versus > 6 years (p = 0.43).
A statistically significant difference in length of MRSP
carriage was found between dogs treated with antimi-
crobials to which the cultured MRSP bacteria were
resistant for a period of three weeks (21 days) or longer
(n = 19) and dogs treated for a shorter period (n = 12)
(p = 0.01). Median length of carriage was 11.3 months
(48.5 weeks) for the “long-term treatment” group and
5.7 months (24.5 weeks) for the group treated for a
shorter period (Figure 4).
Two of the five dogs receiving systemic treatment with
an antimicrobial agent to which their cultured MRSP
isolates were susceptible (tetracycline) were found to be
MRSP-negative on the following sample occasion. The
first dog (dog no 1) was treated for three weeks and was
found to be negative on the very first sample occasion
Figure 1 Dendogram of the 26 pairs of isolates from 26 dogs
compared by pulsed-field gel electrophoresis.
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sample. The second dog (dog No. 31) was treated for 4
weeks in between being sampled at 8.5 and 10 months
(37 and 43 weeks) after the inclusion sample. The dog
was unavailable for further sampling. The remaining
three dogs were found to be MRSP-positive on the sam-
ple occasions following end of treatment. Length of pro-
ven MRSP carriage was nine months (39 weeks)
following 8.5 weeks of treatment (dog No. 5) and
approximately five to six months (23 and 26 weeks) fol-
lowing 4.3 weeks of treatment (dogs No. 30 and 7).
M e d i a nl e n g t ho fc a r r i a g eo fM R S Pf o rt h ef i v ed o g s
that received treatment with tetracycline was 34 weeks,
compared to 49 weeks in non-treated dogs (p = 0.06).
MRSP could be isolated from all sample sites. On 9 of
the in total 73 positive sample occasions, positive
cultures were found from all four sample sites. On 21
occasions MRSP was found from only one of the
s a m p l e ds i t e s .T h en o s ew a st h eo n l ys a m p l es i t et h a t
never yielded a positive culture when all other sites
were negative. MRSP was isolated from the nostrils in
only 38% of the 73 positive sample occasions. From the
corner of the mouth, perineum and pharynx MRSP was
isolated in 58, 63, and 67%, respectively, of the positive
sample occasions.
Nonpurulent wounds were present in 11 dogs on a
total of 20 sampling occasions, excluding the inclusion
samples. Ten dogs had one or several wounds when first
sampled, and five of these still had wounds on the follow-
ing sampling. Two of these dogs were found to be nega-
tive on both of these sample occasions. MRSP was
isolated from wounds in 13 of the 16 positive samplings
of dogs with wounds present (81%). All dogs with a posi-
tive MRSP wound culture also had simultaneous positive
cultures from one or several other sampling sites.
The presence of nonpurulent wounds did not signifi-
cantly increase the length of MRSP carriage (p =0 . 9 4 ) .
It did however significantly increase the number of posi-
tive sample sites (p = 0.003). The median number of
positive sample sites per positive sample occasion,
excluding wounds, in each dog was 2.66 when wounds
were present (9 dogs) and 2.0 when there were no
wounds (18 dogs).
No significant association could be found between the
median number of positive sample sites per sample
occasion and presence vs. absence of dermatitis during
the study (2.00 and 2.33 respectively, p > 0.9).
Discussion
This study shows that dogs can carry MRSP for several
months. Nineteen dogs (61%) were found to be MRSP-
Figure 2 Overview of sampled dogs over months.
Figure 3 Proportion of dogs that were MRSP-negative in
relation to time from inclusion sample. The proportion of dogs
found to be MRSP-negative (y-axis) in relation to time in weeks
from inclusion sample (x-axis). MRSP negativity was defined as the
cultures from all sample sites being MRSP-negative on two
consecutive sample occasions; however, two dogs with one
negative sample occasion each are included. Out of a total of 31
dogs, 17 became MRSP-negative. The last positive sample occasion
for each of the 14 dogs that remained positive when leaving the
study are shown as censored observations.
Figure 4 Length of MRSP carriage from inclusion sample
related to length of antimicrobial treatment. The proportion of
dogs found to be MRSP-negative (y-axis) in relation to time in
weeks from the inclusion sample (x-axis) by length of systemic
treatment with antimicrobial agents to which the MRSP isolates
were resistant. Dogs (n = 19) treated for three weeks (≥ 21 days)
are contrasted to dogs with shorter treatment periods (n = 12).
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lowed for more than 14 months (60 weeks) and
remained positive. The exact length of carriage is not
possible to determine because the period in between
samplings varied depending on practicalities, such as
w h e nt h ed o g sw e r ea v a i l a b l ef o rs a m p l i n g .H o w e v e r ,i t
is worth mentioning that the median time of carriage
was very similar regardless if the first negative sample
(48 weeks) or the last positive sample (45 weeks) was
used as the end of carriage. It is also unknown if, and
for how long, the dogs were already carrying MRSP
before the inclusion sample.
Reinfection of dogs during the study cannot be ruled
out. Contact with other MRSP colonized dogs or
humans might have served as a source of reinfection, as
well as contaminated objects in the household [24]. Re-
infection might also have occurred during visits to the
animal clinics and - hospitals, despite strict hygiene
measures being enforced in connection with all aspects
of handling and caring for the dogs after the initial
MRSP finding (i.e. the inclusion sample) was reported.
Emergence of MRSP has led to several investigations
of the phylogenetic background, diversity and clonal dis-
tribution using different molecular and phenotypical
approaches e.g. [5-8,27]. Conclusive criteria on interpre-
tation of available typing methods for MRSP in relation
to strain persistence are currently lacking. Kadlec et al.
[28] examined genetic relatedness of isolates obtained
from the same dogs during a time period of up to
approximately ten months, and found some SmaIf r a g -
ment patterns to be indistinguishable, and others with
distinct differences. Most studies on MRSP are however
one-point prevalence studies, and to what extent
changes occur over time within a carrier needs to be
elucidated. Further studies investigating MRSP isolates
from the same patient over longer periods of time are
important for increased knowledge and development of
more definitive tools of investigation.
Of the fifteen dogs that were sampled until two conse-
cutive negative results were achieved, twelve were found
to be MRSP-negative within nine months (39 weeks)
from the time of the inclusion sample, the remaining
three within twelve months. Four of these dogs were
found to be MRSP-negative on their very first sample
occasion. According to the four dogs’ medical charts,
the inclusion sample was the first bacteriological sam-
pling made in connection with the relevant diagnosis. It
can therefore not be ruled out that the finding of MRSP
in the inclusion sample of these dogs was a transient
contamination. It is possible that all or some of the 14
dogs leaving the study with a positive result would also
have become MRSP-negative if sampled for longer.
Data published on carriage of MRSP in dogs are lim-
ited, and guidelines regarding the possibility of declaring
a dog as no longer carrying MRSP are lacking. In the
present study, two consecutive negative sample occasions
were used to define the end of MRSP carriage to decrease
the risk of a false negative laboratory result. Possible
causes for a false negative culture result include failure to
identify and further culture potential MRSP colonies at
the laboratory. Because the samples in the study did not
originate from a clinically infected site, there was also an
increased risk of not being able to detect the bacteria of
interest due to overgrowth of other bacteria and fungi,
despite the use of selective enrichment broth and selec-
tive agar. In the present study, cefoxitin was included in
the enrichment broth. Recent studies have demonstrated
that the use of cefoxitin disk diffusion susceptibility test-
ing produces false negative results when screening for
methicillin resistance in veterinary isolates of S. pseudin-
termedius [14,15]. However, this does not mean that
cefoxitin cannot be used in the lower concentration 1
mg/L in the enrichment broth, as in the present study.
Only one of the 31 dogs had a negative culture result
from all four sites between positive sample results (sam-
ple occasion 2 of 4).
In this study, a significant difference in the duration of
MRSP carriage was found between dogs receiving general
treatment with antimicrobial agents to which the bacteria
were resistant for three weeks or longer and dogs treated
for a shorter period with such antimicrobials. Although,
to the best of our knowledge, published studies on use of
antimicrobial drugs selecting for MRSP in dogs are lack-
ing, logical hypotheses and biological data, including
those from human medicine regarding MRSA (methicil-
lin-resistant S. aureus) carriage and infection, support
our finding. The normal skin flora is part of the skin’s
defence mechanisms. The normal bacterial skin flora
occupy microbial niches and inhibit colonisation by
invading organisms [2], and it has been shown that anti-
microbial treatment can enable the survival and colonisa-
tion of pathogenic bacteria resistant to the antimicrobial
agent in question by suppressing part of this flora
[29,30]. Dogs receiving systemic treatment with antimi-
crobials to which the bacterium is resistant may therefore
have a higher risk of carrying, spreading, and developing
clinical infections with MRSP. The risk for facilitating
bacterial growth and thereby prolonging clinically appar-
ent infections by prescribing antimicrobials should also
not be overlooked.
T h er e l a t i v e l ys m a l ls a m p l es i z e( f i v ed o g s )c o m b i n e d
with the variation in sampling strategies limits the possi-
bility of evaluating the effect of treatment with an antimi-
crobial agent to which the MRSP isolates were
susceptible on the length of carriage of the bacteria. It is
however noteworthy that three of the dogs were still
found to be MRSP-positive for several months after the
four to nine week-long treatment had ended. This
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mal microbiota, which would prevent total eradication.
No statistically significant difference in the length of
MRSP carriage was found either between the diagnostic
categories or with the presence (or absence) of non-
purulent wounds or signs of dermatitis during the study.
In human medicine, the risk of becoming colonised and
carrying MRSA on the skin, (and thereby the risk of
spreading the bacteria to other individuals) has been
shown to increase with such skin changes [31,32]. Lloyd
and co-workers [33] found that dogs with superficial
bacterial folliculitis had larger populations of S. interme-
dius (canine S. intermedius are now considered to be S.
pseudintermedius) on their nonlesional skin compared
to clinically normal dogs, and two studies found
increased populations of the bacteria on mucosal sur-
faces in dogs with pyoderma [34,35]. Although our data
do not support an association between the presence of
skin lesions and the length of MRSP carriage the sample
size in each of the groups in our study was relatively
small, resulting in a corresponding limitation in statisti-
cal power. Further studies with larger sample sizes
might provide more information regarding factors asso-
ciated with the length of detectable MRSP carriage.
Nonpurulent wound samples (inclusion samples
excluded) had the highest positive MRSP yield (81%) of
the positive sample occasions, compared to less than
70% for each of the four other sample sites (i.e., the nos-
trils, pharynx, perineum and the corner of the mouth).
The nostrils was found to be the most difficult site to
sample correctly and had the lowest positive yield (38%).
Because almost 20% of the wound samples were nega-
tive, despite the bacteria being found in cultures from
other sites that were sampled simultaneously, we con-
clude that a negative nonpurulent wound culture should
not be used as a definitive criterion for a dog being
MRSP-negative. In a previous study where colonisation
frequency with MRSP was compared in various sample
sites: dorsal skull, the buccal and gingival mucosa, the
distal mucosa of the nares, the ventromedial inguinal
fold, and the external anus, no site was found to be
more likely to carry methicillin-resistant staphylococci
[36]. The reason for discrepancy between this study and
our results is not known.
Conclusions
In conclusion, our study shows that dogs can carry
MRSP for several months without clinical signs. The
presence of wounds or signs of dermatitis did not influ-
ence length of carriage.
Systemic treatment with antimicrobial agents to which
the bacterium was resistant for three weeks (21 days) or
longer was associated with prolonged carriage compared to
dogs treated for a shorter period. In addition, three of five
dogs treated with an antimicrobial to which their MRSP-
isolates were susceptible (tetracycline) were found to still
be MRSP-positive when sampled after the end of treat-
ment. We therefore recommend that systemic antimicro-
bial treatment in dogs with possible or confirmed MRSP
carriage or infection should be avoided when possible.
Based on our results, simultaneous sampling of several
body sites when screening clinically healthy dogs for
MRSP is recommended. Our results also suggest that
the nostrils are not a priority when screening dogs for
MRSP. Furthermore, whenever the culture from the
nostrils was MRSP-positive, MRSP could also be found
in one or more of the other sites.
Additional material
Additional file 1: Table S1. Information on dogs included in the study.
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